UiPath Shares Surge. Is It Too Late to Buy the Stock?

UiPath reported fiscal Q3 revenue of $411 million, up 16% year‑over‑year and ahead of the $392.9M analyst consensus, with adjusted EPS of $0.16 (up 45%) beating the $0.15 consensus. Annualized renewal run rate rose 11% to $1.78 billion, the company added $59M of new ARR, dollar‑based net retention was 107% and gross retention 98%; operating and free cash flow were $28M and cash and marketable securities totaled $1.5B with no debt. Management guided Q4 revenue to $462–467M (midpoint above $463.1M consensus) and ARR to $1.844–1.849B, highlighted accelerating traction in AI agent orchestration (950+ customers building agents) and new products like ScreenpPlay, while valuation sits at a forward P/S of 5.4 (EV/forward‑sales under 4.5).

Analysis

Market Structure: UiPath (PATH) is transitioning RPA incumbency into an AI-agent orchestration niche where winners capture high-margin orchestration and workflow data. Key buyers are large enterprises that run cost-sensitive automation (2,506 customers >$100k ARR; 333 >$1m ARR), while pure-play LLM providers (infrastructure sellers) may lose share on per-task dollars if orchestration routes cheaper RPA bots instead of expensive LLM calls. Valuation (forward P/S 5.4; EV/FS <4.5 after $1.5bn cash) implies the market prices material upside but requires visible ARR acceleration beyond the $59m new ARR run-rate inflection to rerate further.

Risk Assessment: Tail risks include regulatory restrictions on data movement and model access (GDPR-like rulings), supplier concentration (heavy reliance on NVDA/MSFT/GOOGL infra and models) and model-driven cost blowouts if LLM utilization scales unpredictably. Near-term (0–90 days) downside is headline-driven (guidance misses or partner interruptions); medium-term (3–12 months) execution risk centers on monetizing Maestro/ScreenpLay and sustaining DBNR >105%. Hidden dependency: customer contract lengths and professional services mix can mask true revenue conversion.

Trade Implications: Prefer a staged long bias: asymmetric option exposure and disciplined sizing given early-stage AI adoption. Use 6–9 month call spreads 25–35% OTM (size 0.5–1% notional) to capture adoption inflection with capped downside, and consider selling 30–60 day 10% OTM cash-secured puts if willing to acquire below current levels. Pair trade: long PATH (2%) vs short MSFT (1%) to hedge model-provider concentration while keeping net exposure to orchestration.

Contrarian Angles: Consensus assumes agentic AI adoption = linear ARR lift; it may be stepwise with cluster wins (financial services, contact centers) not broad-based in 12 months. Market may be underpricing margin pressure from LLM call costs if customers prefer agents to bots; conversely, it may be overpaying for near-term growth — use event triggers (quarterly ARR beat >2% vs guide or 100+ new enterprise $100k customers) as re-rating signals.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in PATH today, scale to 4–5% only if next quarter ARR midpoint beats guidance by >1% and new ARR >$70m; set a tactical stop-loss at 18% below entry and target 12–18 month horizon.
• Purchase 6–9 month PATH call spreads 25–35% OTM sized to 0.5–1% of portfolio to capture upside from agent adoption while capping premium risk; close if implied vol rises >40% or after 50% intrinsic gain.
• Sell 30–60 day cash-secured PATH puts 10% OTM (size 1–2% of portfolio) to collect premium and acquire shares at a 10% discount if conviction is confirmed by partnership expansion or ARR acceleration.
• Implement pair trade: long PATH 2% vs short MSFT 1% for 3–6 months to hedge GPU/LLM provider concentration risk; rebalance quarterly and unwind the short if PATH outperforms ARR growth thresholds (ARR beat >$20m).